Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist (potassium‑sparing diuretic) presented as an oral tablet for oral use. It is indicated for the management of hypertension and for reducing morbidity in adults with heart failure following myocardial infarction. By selectively blocking aldosterone receptors, it helps control blood pressure and fluid balance, supporting cardiovascular health.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inspra (eplerenone) is used in conditions related to the renin‑angiotensin‑aldosterone system where excess aldosterone contributes to disease. Hypertension: lowers blood pressure by promoting natriuresis while sparing potassium. Heart failure with reduced ejection fraction (post‑myocardial infarction): decreases mortality and hospital readmission by attenuating cardiac remodeling. Cardiovascular risk after myocardial infarction: lowers the incidence of cardiovascular death and recurrent heart‑failure events.

Eplerenone may cause a range of adverse reactions, most of which are related to its effect on electrolyte balance and renal function.

Common Side Effects: - Hyperkalemia: elevated potassium levels. - Hyponatremia: reduced sodium concentration. - Dizziness: light‑headedness, especially upon standing. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe hyperkalemia: risk of cardiac arrhythmia. - Acute kidney injury: sudden loss of renal function. - Allergic reactions: rash, itching, or angioedema. - Gynecomastia: breast tissue enlargement (rare).

When prescribing eplerenone, clinicians should consider several safety measures to minimize risks. - Renal function monitoring: assess serum creatinine and eGFR before initiation and periodically. - Serum potassium checks: measure potassium levels prior to start and during therapy. - Concomitant potassium‑sparing agents: avoid or use with caution to prevent hyperkalemia. - Dose adjustment in elderly: consider lower starting dose due to reduced renal clearance. - Contraindication in severe hyperkalemia: do not use if potassium >5.0 mmol/L. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Eplerenone interacts with several medicines that can alter potassium balance or renal function.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use markedly increases hyperkalemia risk. - Potassium supplements or potassium‑rich salt substitutes: can cause dangerous hyperkalemia. - Spironolactone: additive aldosterone antagonism may lead to excess potassium.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): may reduce renal clearance and raise potassium. - Digoxin: elevated potassium can affect digoxin toxicity. - Diuretics that cause potassium loss (e.g., loop diuretics): may require potassium monitoring.